Compare Adaptive Biotechnologies Corp (ADPT) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs abrdn Physical Palladium Shares ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.19 (market cap $4.04B), while abrdn Physical Palladium Shares ETF trades at $25.13. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | PALL | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $25.45 | $37.18 |
52-Week Low | $12.30 | $19.96 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
PALL (Aberdeen Physical Palladium Shares ETF) trades at $25.15, showing minimal daily movement with a 0.16% gain. Technical indicators show a bullish trend with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. The ETF recently underwent a 1:5 stock split effective May 18, 2026, adjusting share structure while maintaining exposure to physical palladium.
PALL offers exposure to palladium's supply-demand dynamics amid current price weakness, with analysts viewing the 47% decline from January 2026 highs as a potential buying opportunity. Key risks include Federal Reserve policy uncertainty and industrial demand fluctuations. The ETF's physical backing provides direct commodity exposure, though palladium's volatility requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
